auto_awesome_motion View all 3 versions
organization

SYREON

SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG
Country: Hungary
10 Projects, page 1 of 2
  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 824997
    Overall Budget: 1,998,440 EURFunder Contribution: 1,998,440 EUR
    Partners: SYREON, UOXF, INSTITUTE FOR MEDICAL TECHNOLOGY ASSESSMENT BV, DLR, AIT

    HEcoPerMed responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine and seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the requirements of personalised medicine for more compre-hensive cost-effectiveness estimates that incorporate patient and societal perspectives and enhance sustainable affordability of cutting-edge health innovations. HEcoPerMed will provide an overview of and guidance on high-quality methodological approaches for model-based economic evaluations. In three case studies, HEcoPerMedwill apply state-of-the art economic modelling to demonstrate practical and methodological issues in evaluating personalised medicine innovations. The project team will also study existing shortcomings in stimulating the adoption of personalised medicine and pro-pose financial agreements that accelerate its diffusion in European health systems. HEcoPerMed will construct future scenarios, considering the trends and drivers as well as challenges and benefits of personalised medicine for the European social model of care and its financial viability. For a better financial integration of personalised medicine and new economic models, the project team will develop appropriate diffusion and communication strategies to be in direct contact with experts and a wide variety of stakeholders, taking their needs into account while offering new solutions for the players within the European health systems. These comprehensive measures will fill a gap identified by the ICPerMed to support their efforts in the promotion of personalised medicine in Europe and beyond. The project will support health care decision makers to manage their budgets while providing the best possible care for patients in the field of personalised medicine.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 779306
    Overall Budget: 3,017,020 EURFunder Contribution: 3,017,020 EUR
    Partners: UH, UB, SYREON, University of Glasgow, EUR, University of Exeter, Università Luigi Bocconi

    The overarching objective of the COMED project is to push the boundaries of existing methods for cost and outcome analysis of healthcare technologies, both within the Health Technology Assessment (HTA) and Health System Performance (HSP) frameworks and to develop tools to foster the use of economic evaluation in policy making. Within this general agenda, the COMED project focuses on one broad category of healthcare technologies (medical devices) for exemplary, empirical purposes to: (i) improve economic evaluation methods for medical devices in the context of the HTA framework by increasing their methodological quality and integrating data from different data sources; (ii) investigate health system performance through analysis of variation in costs and outcomes across different geographical areas and (iii)strengthen the use of economic evaluation of medical devices in policy making. COMED’s ambition is to develop scientifically rigorous recommendations on what, when and how real world evidence sources can and should be used for assessment of medical devices. COMED’s aim is to develop new methods for assessing patient reported outcomes for mHealth technologies. COMED will provide a comprehensive answer on the main drivers of clinical practice variations across Europe by differentiating between warranted and unwarranted causes of disparities. COMED will develop, for the first time, adequately researched policy advice for the early assessment and conditional reimbursement policy tools in the field of medical devices. The project will expand the geographic scope of evidence generation from a single jurisdiction to collaborative evidence generation throughout Europe. It will have a substantial impact by on public health in Europe, by providing scientifically robust evidence for a wide range of key stakeholders ranging from policy makers to patients and wider public

  • Open Access mandate for Publications
    Funder: EC Project Code: 634753
    Overall Budget: 2,995,680 EURFunder Contribution: 2,995,680 EUR
    Partners: LSHTM, Institute of Oncology Ljubljana, SYREON, SUOMEN SYOPAYHDISTYS -CANCERFORENINGEN I FINLAND RY - CANCER SOCIETY OF FINLAND CSF, AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO, ERASMUS MC, National Institute for Health Development

    Breast, colorectal and cervical cancer cause 250,000 deaths each year, representing 20% of EU-cancer mortality. Although important progress has been made in both detection and treatment, there is persisting inequity in progress to reduce its burden. Screening programmes vary substantially between countries and in most long-term effectiveness of screening has not yet been assessed. The objective of EU-TOPIA is to systematically evaluate and quantify the harms and benefits of the running programmes for breast, cervical, and colorectal cancer in all European countries, and identify ways to improve health outcomes and equity for citizens. We will first identify significant inequities in screening outcomes by assessing the key set of quality indicators for benefits and harms in each country. Using these indicators, outcomes and cost-effectiveness of existing cancer screening programmes in 2015 will be estimated. For this, state-of-the-art models of the natural history of the cancers will be constructed, using country-specific data with and from country-specific experts. Barriers hindering implementation of optimal screening programs will be assessed, leading to road maps for improved screening. These road maps contain feasible changes, e.g., to extend or reduce the program, to change the screen test used or change key quality indicators, to perform activities that reduce screen-related harm or incorporate new developments in screening, and provide policymakers with evidence for increased, decreased or optimized use of screening. Capacity for self-evaluation of screening will be built using three web-based tools (monitoring, model-quantification and barrier assessment) explained and trained in workshops with country representatives, also from the Associated Countries. The project will lead to reduced inequity, reduced number of cancer deaths and over-diagnosed cases, and increase in life years gained and better cost-effectiveness by 2025. That is why we call it EU-TOPIA.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 965014
    Overall Budget: 3,117,340 EURFunder Contribution: 3,117,340 EUR
    Partners: GSCO, AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO, IOCN, ERASMUS MC, Institute of Oncology Ljubljana, SYREON, TOPICUS ZORG, IPH MNE

    Colorectal, breast and cervical cancer cause 155,000 deaths each year in middle income countries (MIC) in Eastern Europe, while there is good evidence that a large proportion could be prevented by organized screening. Although many MIC in Eastern Europe have implemented some form of cancer screening, this screening is often non-organized, leading to lack of data and quality assurance systems. Also, coverage is commonly low and minority groups are not reached. In a previous HORIZON2020 project ‘EU-TOPIA’, we developed road maps to improve cancer screening programmes in Europe. In the current project, EU-TOPIA-EAST, these roadmaps will be refined and translated into action plans for three MICs: Georgia (breast), Romania (cervix) and Montenegro (colorectal). These action plans will take the local health and social system into account by performing detailed barrier and stakeholder analyses, leading to feasible changes to current screening programs. Next, we will implement these action plans: e.g. in Georgia, we will increase coverage of the programme by establishing a new screening unit; in Romania, we will develop new IT infrastructure to allow invitation-based cervical cancer screening; and finally in Montenegro we will establish a new colonoscopy center to increase programme capacity decrease travel time for participants. The implemented programs will be monitored and evaluated using key indicators and sophisticated decision models to predict the long-term and country-wide benefits, harms and cost-effectiveness. During workshops and roundtable discussions for policymakers and screening program coordinators from all countries in Eastern Europe and the Mediterranean to build capacity and upscale the implementation of these intervention(s) in Equitable, Accessible, and SusTainable (EU-TOPIA-EAST) ways. In this way, the project will improve the prevention and early diagnosis of cancer in real-life settings in Eastern European and Mediterranean countries.

  • Open Access mandate for Publications
    Funder: EC Project Code: 634288
    Overall Budget: 5,472,450 EURFunder Contribution: 5,472,450 EUR
    Partners: University of Manchester, SYREON, IHS, MINISTARSTVO ZDRAVSTVA REPUBLIKE HRVATSKE, UiB, EUR, IDIBAPS, TUB, AGENCIJA ZA KVALITETU I AKREDITACIJU U ZDRAVSTVU I SOCIJALNOJ SKRBI

    Over 50 million people in Europe have more than one chronic disease. This number will increase dramatically in the near future. This will increase health care spending to a staggering 20% of GDP. Multi-morbidity becomes the number one threat to population health and economic sustainability of health care systems. New models of care for multi-morbid patients are urgently needed. Given the diversity of Europe’s health and social care systems there is no single model that fits them all. SELFIE aims to improve patient-centred care for patients with multi-morbidity by proposing evidence-based, economically sustainable integrated chronic care (ICC) models that stimulate cooperation across health and social care sectors and are supported by appropriate financing/payment schemes. SELFIE specifically focuses on multi-morbidity, on generating empirical evidence of the impact of ICC and on financing/payment schemes. It is methodologically innovative by applying Multi-Criteria Decision Analysis. SELFIE develops 5 end-results that are adjustable to different care systems in Europe, including CEE: 1. A taxonomy of most promising ICC models for patients with multi-morbidity; this taxonomy includes a “toolkit” of interventions that policy makers can use to build an ICC model that best fits into their own health and social care system 2. A detailed list of options for different financing/payment schemes to support the implementation of ICC for multi-morbidity 3. A technical document on price-setting of ICC models for patients with multi-morbidity 4. A performance assessment tool to monitor goal achievement; this tool includes new indicators that specifically address the quality of care for patients with multi-morbidity 5. Strategies for implementation and change management Patients, informal and professional caregivers, payers and policy makers are involved right from the beginning to ensure that SELFIE addresses the right questions and pave the pathway for implementation.